Search the Newsreel

Xenia Hotels & Resorts (NYSE:XHR) Stock Rating Upgraded by Wells Fargo & Company

XBIO|Xenetic Biosciences Inc|Price:2.640|Chg%:-0.085

Xenetic Biosciences Inc. (XBIO) shows "relatively very healthy" fundamentals and high growth potential, though its valuation is considered "fairly valued" within the Biotechnology & Medical Research industry. The company, focused on immuno-oncology technologies, has seen steady revenue growth and holds significant institutional ownership. Despite …

Crexendo, Inc. Revenue Breakdown – NASDAQ:CXDO

This article provides a detailed revenue breakdown for Crexendo Inc (CXDO) by business segment and geographical region. It highlights that telecommunications services and subscription maintenance and support are the largest revenue contributors, and the United States accounts for the vast majority of the company's …

ETFs Investing in Xencor, Inc. Stocks

This article provides a comprehensive list of ETFs that hold Xencor, Inc. (XNCR) stocks, detailing information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The information presented aims to assist investors …

Xenia Hotels & Resorts stock hits 52-week high at $21.50

Xenia Hotels & Resorts (XHR) stock reached a new 52-week high of $21.50, reflecting a significant 61.36% increase over the past year. This achievement follows strong first-quarter 2026 results where the company exceeded both EPS and revenue expectations. Despite the positive financial performance, the …

Xencor, Inc. Revenue Breakdown – DUS:XE9

Xencor, Inc. (DUS:XE9) generated 106.92 million EUR last year, primarily from its Engineered Antibody Therapeutics segment, marking a slight increase from the previous year. The company's revenue largely originated from the United States. This report provides a breakdown of the company's top segments and …

Can Xenora Minerals (ASX:XRA) Maintain Momentum as Lithium Exploration Progresses?

Xenia Hotels & Resorts Is Maintained at Overweight by Wells Fargo

Wells Fargo has reiterated its "Overweight" rating for Xenia Hotels & Resorts (XHR). This indicates the firm's positive outlook on the company's stock performance. Investors and market watchers may take note of this maintained rating from a prominent financial institution.

Xencor, Inc. (XNCR) Stock Forecasts

Xencor Inc. (XNCR) received a rating increase to "HOLD" from Argus on July 22, 2026. The clinical-stage biopharmaceutical company focuses on developing engineered antibody therapeutics for cancer and autoimmune diseases. Currently, its stock price is $19.54.

Wedbush Reaffirms Their Buy Rating on Xencor (XNCR)

Xenia Hotels & Resorts (XHR) Expected to Post Earnings on Thursday

Xenia Hotels & Resorts (XHR) is scheduled to release its Q2 2026 earnings before market open on Thursday, July 30th, with analysts anticipating $0.245 EPS on $301.48 million in revenue. The company surpassed expectations in the previous quarter and has provided FY 2026 EPS …

Form 4 Nexxen International Ltd. For: 22 July By Investing.com

This article announces the filing of a Form 4 for Nexxen International Ltd. on July 22, 2026. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders. The brief content available does not provide details on the …

(XNCR) Movement as an Input in Quant Signal Sets

Xencor Inc. (NASDAQ: XNCR) is showing strong sentiment across all horizons, supporting an overweight bias according to quantitative analysis. The AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each tailored to …

(XHR) Price Dynamics and Execution-Aware Positioning

This article analyzes Xenia Hotels & Resorts Inc. (NYSE: XHR) stock, identifying a strong near-term sentiment shifting towards long-term positive bias with no resistance levels above the current price, suggesting upside potential. It presents three distinct AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and …

Understanding the Setup: (XENE) and Scalable Risk

This article provides an in-depth analysis of Xenon Pharmaceuticals Inc. (XENE) using AI models to suggest trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, pointing out a significant short setup with a 34.6:1 risk-reward ratio. The analysis includes position, …

Allspring Global Investments Holdings LLC Increases Position in Xenia Hotels & Resorts, Inc. $XHR

Allspring Global Investments Holdings LLC significantly increased its stake in Xenia Hotels & Resorts, Inc. (NYSE:XHR) by 40.2% in the first quarter, now owning 1,360,082 shares valued at $19.898 million. Other institutional investors also adjusted their positions, and analysts have set an average "Buy" …

Xenora Minerals (ASX:XRA) Drops— Is the Sell-Off Hiding a Speculative Opportunity?

Crexendo Inc. (NASDAQ:CXDO) Given Average Recommendation of "Moderate Buy" by Analysts

Crexendo Inc. (NASDAQ:CXDO) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $10.40. The company recently surpassed quarterly earnings and revenue estimates. Despite positive analyst sentiment and strong financial results, there have been significant insider stock sales …

Xencor (XNCR) Updates Its Pipeline, Is The Stock Still Cheap?

Xencor (XNCR) recently updated its pipeline with positive phase I data for XmAb819 and progress on other candidates, leading to significant short-term share price momentum. Despite this, Simply Wall St's analysis suggests the stock is 28.2% undervalued, with a fair value of $28.50 compared …

Nexxen and Acxiom Deepen Partnership, Expanding Omnichannel Audience Intelligence Offering

Nexxen and Acxiom have expanded their partnership to integrate Acxiom’s audience data into Nexxen’s insights tool, Nexxen Discovery. This collaboration aims to provide advertisers with a more dynamic and continuously refreshed view of consumer behavior by combining privacy-aware consumer intelligence with real-time intent signals. …

Nexxen Links Purchase and Household Data to Real-Time Signals

Nexxen announced an expanded partnership with Acxiom, integrating Acxiom’s privacy-aware audience data into Nexxen’s insights tool, Nexxen Discovery. This integration combines interest, purchase, and household-level intelligence with Nexxen's contextual, behavioral, and viewership signals. The collaboration aims to help advertisers refine audiences, extend reach across …

Xenia Hotels (NYSE:XHR) Touches One-Year High on NYSE Composite

Xenia Hotels & Resorts (NYSE:XHR) recently achieved a new one-year high on the NYSE Composite. This milestone is attributed to the ongoing strong performance of its hospitality real estate operations, which focus on premium hotel properties. The company operates as a lodging-focused real estate …

Xencor stock hits 52-week high at 18.83 USD By Investing.com

Xencor Inc.'s stock reached a 52-week high of $18.85, boosting its market capitalization to $1.37 billion, reflecting a 102.97% increase over the past year due to investor optimism and drug development advancements. Despite this, InvestingPro analysis suggests the stock might be overvalued. Separately, Xencor …

Enterprise value to EBIT forward of Nexxen International Ltd. – FWB:7P91

This article provides financial information for Nexxen International Ltd. (FWB:7P91) on TradingView, specifically focusing on its Enterprise Value to EBIT forward metric. It highlights the company's financial overview, documents, news, and community discussions available on the platform. The content emphasizes data provision by ICE …

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) shares surged 16.9% in the last trading session, driven by optimism regarding the progress of its oncology and autoimmune disease pipeline. Key developments include advancements in its lead oncology candidate XmAb819 and progress in immunology with XmAb942. Despite this, the company anticipates …

Nexxen International Ltd. (NEXN) CFO sells 35,000 shares under plan

Nexxen International Ltd.'s CFO, Niri Sagi, sold 35,000 shares of common stock on July 16, 2026, at an average price of $10.3136 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Sagi directly holds 144,066 shares. The sale resulted in a …

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. announced that results from its Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC) have been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail expansion-cohort results evaluating intravenous doses for the recommended …

Xenon Pharmaceuticals (XENE) Q1 2025 earnings summary

Xenon Pharmaceuticals reported a Q1 2025 net loss of $65.0 million, an increase from the previous year, driven by higher R&D and G&A expenses. The company is nearing completion of patient recruitment for its pivotal XTOL-2/X-TOLE2 phase 3 epilepsy study, with top-line results expected …

Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story?

Xencor's antibody engineering platform is expanding into solid-tumor oncology, as evidenced by the upcoming oral presentation of XmAb819 Phase 1 results at the 2026 ESMO Congress and planned pivotal trial. This strategic shift complements ongoing progress in their TL1A programs, indicating a stronger focus …

Crexendo to announce Q2FY26 financial results on August 4

Crexendo, Inc. is scheduled to announce its second quarter 2026 financial results on August 4, 2026, at 4:30 PM ET via a conference call. CEO Jeff Korn, President and COO Doug Gaylor, and CFO Ron Vincent will discuss the quarterly performance. A replay of …

Crexendo, Inc. to Issue Second Quarter 2026 Financial Results on August 4, 2026, at 4:30 PM ET

Crexendo, Inc. announced it will host a conference call on August 4, 2026, at 4:30 PM ET to discuss its second-quarter 2026 financial results. CEO Jeff Korn, President Doug Gaylor, and CFO Ron Vincent will provide remarks and answer questions. A replay of the …

Crexendo sets Q2 call; its solutions support over 7 million end users

Crexendo, Inc. (NASDAQ: CXDO) announced it will hold its second quarter 2026 financial results conference call on August 4, 2026, at 4:30 PM ET. The call will feature remarks from CEO Jeff Korn, President and COO Doug Gaylor, and CFO Ron Vincent, followed by …

Xencor to present Phase 1 XmAb819 data in advanced kidney cancer at ESMO 2026

Xencor plans to present Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma at ESMO 2026 in an oral presentation. The abstract will be released on October 18, with the full presentation occurring between October 23-27 in Madrid. These results are …

Xenetic Biosciences (XBIO) Slides 1% as Shares Approach Key Support - Investment Factor

Sagi Niri Sells 106,345 Shares of Nexxen International Ltd (NEXN)

Sagi Niri, the CFO of Nexxen International Ltd (NEXN), sold 106,345 shares of the company on July 15, 2026, and now holds 179,066 shares. This transaction follows 13 insider sales and no insider purchases over the past year. Nexxen International Ltd is currently considered …

Form 144 Nexxen International Ltd. For: 16 July By Investing.com

This article announces the filing of Form 144 for Nexxen International Ltd. on July 16. It is a brief administrative notice from Investing.com, providing no further details about the Form 144 content itself other than the company and date. The article also includes links …